FIELD: medicine; oncology.
SUBSTANCE: invention relates to a method of treating cancer expressing PSMA in a patient in need of such treatment. The method involves administering to a patient a therapeutically effective amount of a compound of formula 1, wherein the compound forms a complex with a metal, wherein the metal is 177Lu, the therapeutically effective amount being from about 7 GBq to about 8 GBq of 177Lu radioactivity. The compound is administered in a regimen of once every 4–8 weeks for about 4–6 cycles of the regimen, and the method provides a total dose of 177Lu radioactivity of about 28 GBq to about 48 GBq.
EFFECT: invention makes it possible to achieve a beneficial effect, which may include overall patient survival, tumor growth inhibition, stable disease, partial patient response to therapy, complete patient response to therapy, and disease control.
31 cl, 1 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER | 2019 |
|
RU2825637C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822092C2 |
| METHODS AND COMPOSITIONS FOR CAR-T-CELL THERAPY | 2017 |
|
RU2792653C2 |
| EFFICIENT SYNTHESIS OF ETHYLENEDICYSTEINE-SUGAR CONJUGATES FOR IMAGING AND THERAPY | 2013 |
|
RU2674673C2 |
| COMPLEX CONTAINING A PSMA-TARGETING COMPOUND BOUND TO A LEAD OR THORIUM RADIONUCLIDE | 2018 |
|
RU2795398C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822091C2 |
| RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS AND THEIR USE | 2018 |
|
RU2804297C2 |
| PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
| METHOD FOR TREATING CANCER BY TARGETING SUPPRESSOR CELLS OF MYELOID ORIGIN | 2017 |
|
RU2776899C2 |
| COMBINATION THERAPY USING LIPOSOMAL IRINOTECAN AND PARP INHIBITOR FOR THE TREATMENT OF CANCER | 2016 |
|
RU2760185C2 |
